公开(公告)号：US20250064947A1

公开(公告)日：2025-02-27

申请号：US18812114

申请日：2024-08-22

Applicant: Glaxosmithkline Intellectual Property Development Limited

Inventor： Christina Ng Di Marco ,  Matthew Robert Sender ,  Brandon James Turunen

IPC: A61K47/55 ,  A61K39/395 ,  A61K47/60

Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer.

公开(公告)号：US12234290B2

公开(公告)日：2025-02-25

申请号：US17187669

申请日：2021-02-26

Applicant: Avidity Biosciences, Inc.

Inventor： Andrew John Geall ,  Venkata Ramana Doppalapudi ,  David Sai-Ho Chu ,  Michael Caramian Cochran ,  Rachel Elizabeth Johns ,  Palani Balu ,  Rob Burke ,  Beatrice Diana Darimont

IPC: C07K16/28 ,  A61K31/7088 ,  A61K31/713 ,  A61K39/00 ,  A61K47/60 ,  A61K47/68 ,  A61K48/00 ,  A61P35/00 ,  A61P35/02 ,  C07K16/30 ,  C12N15/113 ,  C12N15/88

Abstract: Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

公开(公告)号：US12233115B2

公开(公告)日：2025-02-25

申请号：US18368347

申请日：2023-09-14

Applicant: Extend Biosciences, Inc.

Inventor： Tarik Soliman ,  Daniel B. Hall ,  Rachel Covitz ,  Garry Musso ,  Caroline Hill ,  Ahmet Vakkasoglu ,  Poul Strange ,  Tilmann M. Brotz

IPC: A61K38/29 ,  A61K47/55 ,  A61K47/60

Abstract: The invention provides a long-acting parathyroid hormone peptide (PTH) that is retained in a subject's blood serum for periods of time that greatly exceed the natural hormone. The long-acting PTH is conjugated to at the carbon 3 position of a non-hormonal vitamin D via a scaffold of discreet length that facilitates its purification, detection, solubility, and efficacy at the PTH receptor (PTHR). The PTH may be conjugated to the non-hormonal vitamin D via a 36 mer poly(ethylene glycol) moiety (PTH-PEG36-VitD). The invention also provides optimized manufacturing methods and formulations. The PTH-PEG36-VitD has a vastly-improved serum half-life and bioavailability when compared to a non-conjugated PTH peptide. PTH-PEG36-VitD also significantly increases serum calcium, reduces urinary calcium, and reduces serum phosphate.

公开(公告)号：US12233109B2

公开(公告)日：2025-02-25

申请号：US17479428

申请日：2021-09-20

Applicant: The Johns Hopkins University

Inventor： Seulki Lee ,  Ted M. Dawson ,  Han Seok Ko ,  Valina L. Dawson ,  Seung Pil Yun ,  Magdalena Scully

IPC: A61K38/26 ,  A61K9/00 ,  A61K38/38 ,  A61K47/60 ,  A61K47/68 ,  A61P25/16 ,  A61P25/28

Abstract: The present invention relates to compositions and methods for treating neurodegenerative conditions using GLP-1r agonists. In certain embodiments, long-acting GLP-1r agonists have neuroprotective and disease modifying effects on the central nervous system.

公开(公告)号：US20250059263A1

公开(公告)日：2025-02-20

申请号：US18758893

申请日：2024-06-28

Applicant: École Polytechnique Fédérale de Lausanne (EPFL)

Inventor： Jeffrey A. Hubbell ,  Stephan Kontos ,  Karen Y. Dane

IPC: C07K16/18 ,  A61K9/107 ,  A61K9/51 ,  A61K38/00 ,  A61K39/00 ,  A61K47/60 ,  A61K47/62 ,  A61K47/64 ,  A61K47/68 ,  A61K47/69 ,  C07K7/08 ,  C07K14/62 ,  C07K14/74 ,  C07K16/28 ,  C12N9/82

Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

公开(公告)号：US20250057914A1

公开(公告)日：2025-02-20

申请号：US18899589

申请日：2024-09-27

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： Michael K. Schultz ,  Frances L. Johnson ,  Somya Kapoor ,  Dongyoul Lee ,  Mengshi Li ,  Molly Martin

IPC: A61K38/12 ,  A61K47/54 ,  A61K47/60 ,  A61K51/04 ,  A61P35/00 ,  C07K16/28

Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof.
The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I. T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits, and uses of the conjugate of Formula I.

公开(公告)号：US20250057756A1

公开(公告)日：2025-02-20

申请号：US18933195

申请日：2024-10-31

Applicant: Cartesian Therapeutics, Inc.

Inventor： Lloyd Johnston ,  Takashi Kei Kishimoto ,  Werner Cautreels ,  Earl Sands

IPC: A61K9/00 ,  A61K9/16 ,  A61K9/51 ,  A61K31/436 ,  A61K38/44 ,  A61K45/06 ,  A61K47/60 ,  A61P19/06 ,  A61P37/06 ,  B82Y5/00

Abstract: Provided herein are methods and compositions and kits related to uricase compositions and/or compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions and kits for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.

公开(公告)号：US12226457B2

公开(公告)日：2025-02-18

申请号：US16866764

申请日：2020-05-05

Applicant: Ascendis Pharma Endocrinology Division A/S

Inventor： Grethe Nørskov Rasmussen ,  Susanne Kindermann ,  Harald Rau ,  Thomas Wegge

IPC: A61K38/27 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K45/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K47/60 ,  A61M5/19

Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.

公开(公告)号：US20250049968A1

公开(公告)日：2025-02-13

申请号：US18921938

申请日：2024-10-21

Applicant: The Board of Regents of the University of Oklahoma

Inventor： Venkateswararao Eeda ,  Vibhudutta Awasthi

IPC: A61K51/04 ,  A61K9/127 ,  A61K47/54 ,  A61K47/60 ,  A61P9/00

Abstract: Analogs and derivatives of omecamtiv mecarbil (OM), including an 18F-labeled analog, and methods of synthesis thereof. Cardiac myosin targeting vectors comprising a lipid anchoring/solubilizing moiety conjugated to a head made of OM or the OM analog or derivative. Liposomes comprising a cardiac-treating cargo molecule and the cardiac myosin targeting vector. Methods of treating a cardiac condition or disease in a subject by administering to the subject the cardiac-treating cargo molecule and the cardiac myosin targeting vector. Methods of synthesizing an 18F-labeled analog of OM.

公开(公告)号：US20250049934A1

公开(公告)日：2025-02-13

申请号：US18718703

申请日：2022-12-14

Applicant: Nektar Therapeutics ,  Eli Lilly and Company

Inventor： Ali Ashrafzadeh ,  Steven Witt Dodd ,  Kimberley Anne Jackson ,  Stacey Masaaki Kaneshiro ,  Paul Alan Klekotka ,  Brian Leslie Kotzin ,  Carsten Schmitz ,  Jonathan Zalevsky

IPC: A61K47/60 ,  A61K9/00 ,  A61K47/12 ,  A61K47/26 ,  A61P17/06 ,  A61P37/06 ,  A61P37/08

Abstract: The instant disclosure provides selective Treg stimulator compositions, including RUR20kD-IL-2 and related compositions, and rezpegaldesleukin, and formulations and dosing regimens for methods of using these compositions, for example, for treating autoimmune diseases, including atopic dermatitis.